The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.



Latest Headlines

Latest Headlines

Bayer up on Pfizer buyout talk

Market matchmakers won't leave Pfizer alone. Today, rumors are circulating that the drugmaker is

Pfizer withdraws dalbavancin app

Pfizer has withdrawn U.S. and European marketing applications for dalbavancin--a drug for complicated skin and skin structure infections in adults--following feedback from regulatory agencies. The

Pfizer's Fablyn may be linked to more deaths

The FDA is taking a critical look at Pfizer and Ligand's Fablyn, an osteoporosis drug the companies developed together that has been submitted to the FDA. Ahead of Monday's advisory panel meeting,

Pfizer's 2007 Lipitor Ad

Pfizer's Lipitor commercial, which featured Dr. Robert Jarvik. Both Pfizer and Jarvik drew fire from critics who questioned Dr. Jarvik's endorsement of a medication they argued he is neither

Medivation shares soar on $725M Pfizer deal

Medivation investors were treated to a 31 percent spike in their stock value after news broke this morning of a big licensing deal with

Pfizer's 2008 Lipitor Ad

The latest Lipitor ad, which features John Erlendson, a 58-year-old California talent agent rather than Dr. Robert Jarvik. Video courtesy of Related Articles and Video:

Pfizer's Lipitor ad returns, sans celebrity

When word leaked that Pfizer's celebrity doctor spokesperson had never actually practiced medicine, controversy heated up. The drug maker

Pfizer, Merck go for indirect ads

The new trend in drug marketing isn't drug marketing at all. New commercials from Pfizer and Sanofi-Aventis, plus what can only be called a "jewelry campaign" from Merck, show that pharma companies

Pfizer's "my time to quit" television ad

Pfizer fails again in late-stage anti-clotting trial

There's more bad news for Pfizer's pipeline. An anti-clotting drug it is developing with Bristol-Myers